NanoDrops Revenue

About NanoDrops

NanoDrops is a medtech company pioneering the first reversible and repeatable vision correction technology for presbyopia, eliminating the need for reading glasses. NanoDrops’ unique solution retains the shape of the cornea, unlike traditional laser surgery. That makes the procedure reversible, repeatable and micro-invasive – empowering patients to adjust their vision as it evolves with age and giving both patients and ophthalmologists peace of mind. Up to now, when patients in their 40s or older find themselves needing to hold their book further away or magnify the text on their screen in order to read properly, reading glasses have long been the go-to solution. Presbyopia, or age-related farsightedness, seems to have largely been sidelined by the vast technological advances in medicine. Yet refractive clinics already have the existing LASIK platforms that can treat presbyopia, in combination with NanoDrops’ proprietary nanoparticle filler, which activates a corneal imprint. This solution, currently at a pre-clinical stage, gives the clinics an opportunity to expand their customer base to patients who may otherwise not be considered ideal candidates for laser eye surgery. NanoDrops has received $8.1 million in seed capital from Sanara Capital, the Israel Innovation Authority and private investors. The company was founded in 2020 by refractive and cataract surgeon Prof. David Smadja, MD, chair of the Innovation Committee of the International Society of Refractive Surgery, president of the Israeli Society of Refractive Surgery and associate professor of ophthalmology at Hadassah Medical Center in Jerusalem. Investors looking to work with NanoDrops are invited to contact NanoDrops CEO Daria Lemann-Blumenthal, who previously co-founded and scaled the groundbreaking medical device company BELKIN Vision, which was acquired by global eye care leader Alcon in 2024 for $466 million.

View contact profiles from NanoDrops